Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical-stage biopharmaceutical company focused on innovative drug development and novel drug delivery systems. Established in 2006, SPARC emerged from a demerger with Sun Pharmaceutical Industries, enabling it to concentrate on creating new chemical entities and advancing novel drug delivery systems for global markets. Over the years, SPARC has attained several key U.S. FDA approvals, including DOCEFREZ, PICN, ELEPSIA XR, and XELPROS, although some faced regulatory challenges linked to compliance issues at manufacturing sites.
SPARC is actively involved in strategic collaborations and licensing agreements, such as with Sun Pharmaceutical Industries and Visiox Pharma, to commercialize products like ELEPSIA XR and XELPROS. It has also engaged in in-licensing agreements, obtaining rights for SCD-044 and entering partnerships for commercialization rights in various regions. Despite facing regulatory hurdles, SPARC continues to advance its pipeline, with notable progress in oncology and central nervous system disorders. As of FY23, after significant equity changes, Shanghvi Finance Private Limited is no longer the holding company of SPARC.
